Literature DB >> 22572740

Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging.

Peng Gao1, Raymond Yee, Lorne Gula, Andrew D Krahn, Allan Skanes, Peter Leong-Sit, George J Klein, John Stirrat, Nowell Fine, Luljeta Pallaveshi, Gerald Wisenberg, Terry R Thompson, Frank Prato, Maria Drangova, James A White.   

Abstract

BACKGROUND: Scar signal quantification using late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) identifies patients at higher risk of future events, both in ischemic cardiomyopathy (ICM) and nonischemic dilated cardiomyopathy (DCM). However, the ability of scar signal burden to predict events in such patient groups at the time of referral for implantable cardioverter-defibrillator (ICD) has not been well explored. This study evaluates the predictive use of multiple scar quantification measures in ICM and DCM patients being referred for ICD. METHODS AND
RESULTS: One hundred twenty-four consecutive patients referred for ICD therapy (59 with ICM and 65 with DCM) underwent a standardized LGE-CMR protocol with blinded, multithreshold scar signal quantification and, for those with ICM, peri-infarct signal quantification. Patients were followed prospectively for the primary combined outcome of appropriate ICD therapy, survived cardiac arrest, or sudden cardiac death. At a mean follow-up of 632 ± 262 days, 18 patients (15%) had suffered the primary outcome. Total scar was significantly higher among those suffering a primary outcome, a relationship maintained within each cardiomyopathy cohort (P<0.01 for all comparisons). Total scar was the strongest independent predictor of the primary outcome and demonstrated a negative predictive value of 86%. In the ICM subcohort, peri-infarct signal showed only a nonsignificant trend toward elevation among those having a primary end point.
CONCLUSIONS: Myocardial scar quantification by LGE-CMR predicts arrhythmic events in patients being evaluated for ICD eligibility irrespective of cardiomyopathy etiology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22572740     DOI: 10.1161/CIRCIMAGING.111.971549

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  56 in total

1.  Cardioverter-defibrillator does not improve short-term survival among patients with non-ischemic cardiomyopathy and reduced left ventricular ejection fraction.

Authors:  Clemens Jilek; Thorsten Lewalter; Matthias Pauschinger; Wolfgang von Scheidt; Lutz Frankenstein; Otmar Pfister; Rainer Hambrecht; Oliver Bruder; Johannes Brachmann; Andreas Hartmann; Ruth Strasser; Matthias Hochadel; Jochen Senges
Journal:  Clin Res Cardiol       Date:  2019-06-24       Impact factor: 5.460

Review 2.  Non-invasive evaluation of arrhythmic risk in dilated cardiomyopathy: From imaging to electrocardiographic measures.

Authors:  Massimo Iacoviello; Francesco Monitillo
Journal:  World J Cardiol       Date:  2014-07-26

3.  Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Razi Khan; David Massel; John Stirrat; David Scholl; Gerald Wisenberg; Terry Thompson; Maria Drangova; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2012-08-09       Impact factor: 2.357

Review 4.  Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.

Authors:  Min-Seok Kim; Ju-Hee Lee; Eung Ju Kim; Dae-Gyun Park; Sung-Ji Park; Jin Joo Park; Mi-Seung Shin; Byung Su Yoo; Jong-Chan Youn; Sang Eun Lee; Sang Hyun Ihm; Se Yong Jang; Sang-Ho Jo; Jae Yeong Cho; Hyun-Jai Cho; Seonghoon Choi; Jin-Oh Choi; Seong Woo Han; Kyung Kuk Hwang; Eun Seok Jeon; Myeong-Chan Cho; Shung Chull Chae; Dong-Ju Choi
Journal:  Korean Circ J       Date:  2017-09-18       Impact factor: 3.243

5.  Can we still rely on the ECG for detecting past myocardial injury?

Authors:  Gautam G Lalani; Andrew M Kahn; Sanjiv M Narayan
Journal:  JACC Cardiovasc Imaging       Date:  2013-02-20

6.  Evaluation of the ECG based Selvester scoring method to estimate myocardial scar burden and predict clinical outcome in patients with left bundle branch block, with comparison to late gadolinium enhancement CMR imaging.

Authors:  Uzma Chaudhry; Pyotr G Platonov; Robert Jablonowski; Jean-Philippe Couderc; Henrik Engblom; Xiajuang Xia; Björn Wieslander; Brett D Atwater; David G Strauss; Jesper Van der Pals; Martin Ugander; Marcus Carlsson; Rasmus Borgquist
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-03-01       Impact factor: 1.468

7.  Comparison of semi-automated scar quantification techniques using high-resolution, 3-dimensional late-gadolinium-enhancement magnetic resonance imaging.

Authors:  Martin Rajchl; John Stirrat; Maged Goubran; Jeff Yu; David Scholl; Terry M Peters; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2014-10-12       Impact factor: 2.357

8.  Magnetic resonance estimates of the extent and heterogeneity of scar tissue in ICD patients with ischemic cardiomyopathy predict ventricular arrhythmia.

Authors:  Tawfiq Zeidan-Shwiri; Yuesong Yang; Ilan Lashevsky; Ehud Kadmon; Darren Kagal; Alexander Dick; Avishag Laish Farkash; Gideon Paul; Donsheng Gao; Mohammed Shurrab; David Newman; Graham Wright; Eugene Crystal
Journal:  Heart Rhythm       Date:  2015-01-09       Impact factor: 6.343

9.  Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.

Authors:  Da-Jun Hu; Jing Xu; Wei Du; Jian-Xin Zhang; Min Zhong; Ya-Nan Zhou
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-26       Impact factor: 2.357

10.  Cardiac MRI scar patterns differ by sex in an implantable cardioverter-defibrillator and cardiac resynchronization therapy cohort.

Authors:  Zak Loring; David G Strauss; Gary Gerstenblith; Gordon F Tomaselli; Robert G Weiss; Katherine C Wu
Journal:  Heart Rhythm       Date:  2013-01-08       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.